🚨 Biphasic Anaphylaxis Timing Simulator

Initial Reaction and Epinephrine Response

The first phase begins the severity timeline this simulator tracks.

• 1st line: Epinephrine (IM injection, anterolateral thigh)
• <1 h: Onset to peak (typical first-phase timing)
• 5–15 min: Redosing interval (if inadequate response)
• 1–20%: Biphasic incidence (wide reported range)

Acute phase overview

Short placeholder describing the acute anaphylactic reaction and initial treatment.

Placeholder highlight on early epinephrine timing.

The Symptom-Free Quiet Interval Window

Placeholder sentence on the asymptomatic gap after initial improvement.

• 1–8 h: Typical interval (most common reported range)
• 72 h: Max reported gap (outer bound for monitoring)
• Absent: Symptom status (placeholder clinical state)
• High: False reassurance risk (placeholder caution note)

Why symptoms disappear

Placeholder text on transient mediator clearance during the quiet interval.

Second-Phase Mediator Resurgence Risk

Placeholder sentence on late-phase mediator release mechanisms.

• Cytokines: Late mediators (placeholder mediator class)
• Variable: Severity vs phase 1 (can be milder or worse)
• Severity: Risk factor (higher initial severity raises risk)
• Delayed epi: Risk factor (placeholder secondary factor)

Resurgence mechanism

Placeholder text describing late-phase inflammatory mediator resurgence.

Placeholder highlight on severity-linked recurrence risk.

Recurrence Timing Across the 1–72 Hour Range

Placeholder sentence on the broad reported timing distribution.

• 1–72 h: Reported range (literature-wide window)
• 6–12 h: Most common (placeholder typical cluster)
• ~10 h: Median estimate (placeholder summary figure)
• >48 h: Rare late cases (placeholder tail cases)

Timing distribution

Placeholder text on why recurrence timing varies so widely between patients.

Observation Period Decision-Making

Placeholder sentence on choosing a safe observation duration.

• 4–6 h: Standard observation (placeholder default duration)
• 24 h: Extended observation (placeholder high-risk duration)
• Severity: Decision driver (placeholder key factor)
• Symptom-free: Discharge criteria (placeholder criterion)

Balancing risk and resources

Placeholder text on clinical decision-making for discharge timing.

Placeholder highlight on individualized observation planning.